Export Ready — 

Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.

Bibliographic Details
Main Author: Tavares, A
Publication Date: 1992
Other Authors: Galvão, M
Format: Article
Language: por
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307
Summary: In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods for virus inactivation. We report these methods with special attention to their safety, and mention the new perspectives of treatment with recombinant DNA FVIII:C and ultimately by gene insertion therapy.
id RCAP_887e66acb8dcf873d1a9c8c51a6aebe4
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/3307
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C.In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods for virus inactivation. We report these methods with special attention to their safety, and mention the new perspectives of treatment with recombinant DNA FVIII:C and ultimately by gene insertion therapy.In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods for virus inactivation. We report these methods with special attention to their safety, and mention the new perspectives of treatment with recombinant DNA FVIII:C and ultimately by gene insertion therapy.Ordem dos Médicos1992-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307oai:ojs.www.actamedicaportuguesa.com:article/3307Acta Médica Portuguesa; Vol. 5 No. 11 (1992): Novembro; 587-90Acta Médica Portuguesa; Vol. 5 N.º 11 (1992): Novembro; 587-901646-07580870-399Xreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307/2633Tavares, AGalvão, Minfo:eu-repo/semantics/openAccess2022-12-20T11:02:02Zoai:ojs.www.actamedicaportuguesa.com:article/3307Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T10:38:52.235671Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.
Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C.
title Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.
spellingShingle Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.
Tavares, A
title_short Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.
title_full Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.
title_fullStr Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.
title_full_unstemmed Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.
title_sort Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates.
author Tavares, A
author_facet Tavares, A
Galvão, M
author_role author
author2 Galvão, M
author2_role author
dc.contributor.author.fl_str_mv Tavares, A
Galvão, M
description In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods for virus inactivation. We report these methods with special attention to their safety, and mention the new perspectives of treatment with recombinant DNA FVIII:C and ultimately by gene insertion therapy.
publishDate 1992
dc.date.none.fl_str_mv 1992-12-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307
oai:ojs.www.actamedicaportuguesa.com:article/3307
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/3307
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307/2633
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 5 No. 11 (1992): Novembro; 587-90
Acta Médica Portuguesa; Vol. 5 N.º 11 (1992): Novembro; 587-90
1646-0758
0870-399X
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833591089774198784

Similar Items